BlackRock, Inc. Reports 5.8% Ownership in OCULAR THERAPEUTIX, INC

BlackRock, Inc. has filed a Schedule 13G/A amendment reporting a 5.8% ownership in OCULAR THERAPEUTIX, INC. The filing indicates that BlackRock beneficially owns 10,170,232 shares of common stock, with sole voting power over 9,950,244 shares and sole dispositive power over all 10,170,232 shares. The filing also notes that various persons have the right to receive dividends or direct the sale of these shares, but no single person's interest exceeds 5% of the total outstanding shares. The amendment was signed by Spencer Fleming, Managing Director, on October 17, 2025.